IS8843A - Hálfmálmaprótínasa hindra mót - Google Patents

Hálfmálmaprótínasa hindra mót

Info

Publication number
IS8843A
IS8843A IS8843A IS8843A IS8843A IS 8843 A IS8843 A IS 8843A IS 8843 A IS8843 A IS 8843A IS 8843 A IS8843 A IS 8843A IS 8843 A IS8843 A IS 8843A
Authority
IS
Iceland
Prior art keywords
alkyl
alkylaryl
cor
optionally substituted
bond
Prior art date
Application number
IS8843A
Other languages
English (en)
Inventor
Simon Gaines
Ian Peter Holmes
Stephen Lewis Martin
Stephen Paul Watson
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of IS8843A publication Critical patent/IS8843A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
  • Anti-Oxidant Or Stabilizer Compositions (AREA)
  • Soft Magnetic Materials (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Lubricants (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
IS8843A 2003-09-13 2009-08-19 Hálfmálmaprótínasa hindra mót IS8843A (is)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0321538.1A GB0321538D0 (en) 2003-09-13 2003-09-13 Therapeutically useful compounds

Publications (1)

Publication Number Publication Date
IS8843A true IS8843A (is) 2009-08-19

Family

ID=29227079

Family Applications (2)

Application Number Title Priority Date Filing Date
IS8268A IS2622B (is) 2003-09-13 2006-01-26 Hálfmálmprótínasa hindra mót
IS8843A IS8843A (is) 2003-09-13 2009-08-19 Hálfmálmaprótínasa hindra mót

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IS8268A IS2622B (is) 2003-09-13 2006-01-26 Hálfmálmprótínasa hindra mót

Country Status (29)

Country Link
US (3) US7601729B2 (is)
EP (3) EP1663970B1 (is)
JP (3) JP2007505081A (is)
KR (3) KR20130079628A (is)
CN (1) CN1849306B (is)
AT (2) ATE413384T1 (is)
AU (1) AU2004272280C1 (is)
BR (1) BRPI0413791A (is)
CA (1) CA2538315C (is)
CY (1) CY1109400T1 (is)
DE (2) DE602004031991D1 (is)
DK (1) DK1663970T3 (is)
ES (2) ES2314436T3 (is)
GB (1) GB0321538D0 (is)
HK (1) HK1092141A1 (is)
HR (1) HRP20080668T3 (is)
IL (1) IL173305A (is)
IS (2) IS2622B (is)
MA (1) MA28039A1 (is)
MX (1) MXPA06002458A (is)
NO (1) NO20060540L (is)
NZ (2) NZ573479A (is)
PL (1) PL1663970T3 (is)
PT (1) PT1663970E (is)
RU (2) RU2370488C2 (is)
SG (1) SG145685A1 (is)
SI (1) SI1663970T1 (is)
WO (1) WO2005026120A1 (is)
ZA (1) ZA200602070B (is)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0321538D0 (en) * 2003-09-13 2003-10-15 Glaxo Group Ltd Therapeutically useful compounds
CA2598518C (en) * 2005-02-22 2015-04-21 Ranbaxy Laboratories Limited 5-phenyl-pentanoic acid derivatives as matrix metalloproteinase inhibitors for the treatment of asthma and other diseases
JP5399902B2 (ja) * 2006-08-22 2014-01-29 ランバクシー ラボラトリーズ リミテッド マトリックスメタロプロテイナーゼ阻害剤
AU2013200728B2 (en) * 2006-08-22 2014-12-18 Sun Pharmaceutical Industries Limited Matrix metalloproteinase inhibitors
CN103450077B (zh) 2007-06-08 2016-07-06 满康德股份有限公司 IRE-1α抑制剂
FR2949463B1 (fr) * 2009-08-26 2011-09-16 Commissariat Energie Atomique Inhibiteurs de mmp
EP2598493A1 (en) 2010-07-30 2013-06-05 Ranbaxy Laboratories Limited Matrix metalloproteinase inhibitors
BR112013006932A2 (pt) 2010-09-24 2016-07-12 Ranbaxy Lab Ltd composto composição farmacêutica e processo para preparar um composto
WO2014083229A1 (es) 2012-11-28 2014-06-05 Administración General De La Comunidad Autónoma De Euskadi Uso de inhibidores de metaloproteasas en el tratamiento de enfermedades hepáticas poliquísticas
CN113666938A (zh) 2016-02-12 2021-11-19 细胞动力学股份有限公司 四氢异喹啉衍生物
CN110769866B (zh) * 2017-06-13 2022-07-29 爱惜康有限责任公司 具有可控愈合的外科缝合器

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4102024A1 (de) * 1991-01-24 1992-07-30 Thomae Gmbh Dr K Biphenylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
WO1995029901A1 (en) * 1994-04-28 1995-11-09 Uniroyal Chemical Company, Inc. Fungicidal azole derivatives
WO1997020815A1 (en) * 1995-12-06 1997-06-12 Astra Pharmaceuticals Ltd. Compounds
BR9708790A (pt) 1996-04-19 1999-08-03 Akzo Nobel Nv Composto uso de um composto e formulação farmacêutica
HRP970246B1 (en) * 1996-05-15 2002-04-30 Bayer Ag Substituted oxobutric acids as matrix metalloprotease inhibitors
US6242616B1 (en) 1996-12-03 2001-06-05 The Trustees Of The University Of Pennsylvania Synthetic techniques and intermediates for polyhydroxy, dienyl lactone derivatives
US6096904A (en) 1996-12-03 2000-08-01 The Trustees Of The University Of Pennsylvania Synthetic techniques and intermediates for polyhydroxy, dienyl lactone derivatives
US20050065353A1 (en) 1996-12-03 2005-03-24 Smith Amos B. Synthetic techniques and intermediates for polyhydroxy dienyl lactones and mimics thereof
US5789605A (en) 1996-12-03 1998-08-04 Trustees Of The University Of Pennsylvania Synthetic techniques and intermediates for polyhydroxy, dienyl lactones and mimics thereof
US6870058B2 (en) 1996-12-03 2005-03-22 The Trustees Of The University Of Pennsylvania Compounds which mimic the chemical and biological properties of discodermolide
US5804581A (en) * 1997-05-15 1998-09-08 Bayer Corporation Inhibition of matrix metalloproteases by substituted phenalkyl compounds
US6608052B2 (en) * 2000-02-16 2003-08-19 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as anti-inflammatory agents
MXPA03009361A (es) 2001-04-13 2004-01-29 Boehringer Ingelheim Pharma Compuestos de urea utilies como agentes anti-inflamatorios.
AU2003261319A1 (en) 2002-08-01 2004-02-23 Bristol-Myers Squibb Company Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme
WO2004046091A2 (en) * 2002-11-19 2004-06-03 Galderma Research & Development, S.N.C. Biaromatic compounds which activate ppar-gama type receptors, and use thereof in cosmetic or pharmaceutical compositions
GB0312654D0 (en) * 2003-06-03 2003-07-09 Glaxo Group Ltd Therapeutically useful compounds
GB0314488D0 (en) 2003-06-20 2003-07-23 Glaxo Group Ltd Therapeutically useful compounds
GB0319069D0 (en) 2003-08-14 2003-09-17 Glaxo Group Ltd Therapeutically useful compounds
GB0321538D0 (en) * 2003-09-13 2003-10-15 Glaxo Group Ltd Therapeutically useful compounds
CA2598518C (en) 2005-02-22 2015-04-21 Ranbaxy Laboratories Limited 5-phenyl-pentanoic acid derivatives as matrix metalloproteinase inhibitors for the treatment of asthma and other diseases
JP5399902B2 (ja) 2006-08-22 2014-01-29 ランバクシー ラボラトリーズ リミテッド マトリックスメタロプロテイナーゼ阻害剤

Also Published As

Publication number Publication date
IL173305A (en) 2011-01-31
US8263602B2 (en) 2012-09-11
RU2008146479A (ru) 2010-06-20
NZ573479A (en) 2010-09-30
MXPA06002458A (es) 2006-06-20
BRPI0413791A (pt) 2006-11-07
ES2314436T3 (es) 2009-03-16
IL173305A0 (en) 2006-06-11
GB0321538D0 (en) 2003-10-15
ZA200602070B (en) 2007-05-30
NZ545211A (en) 2009-01-31
KR20060120648A (ko) 2006-11-27
US8343986B2 (en) 2013-01-01
AU2004272280B2 (en) 2011-04-21
EP2042488B1 (en) 2011-03-23
JP2012107031A (ja) 2012-06-07
RU2370488C2 (ru) 2009-10-20
DK1663970T3 (da) 2009-01-12
AU2004272280A1 (en) 2005-03-24
ES2362954T3 (es) 2011-07-15
HK1092141A1 (en) 2007-02-02
CN1849306A (zh) 2006-10-18
AU2004272280C1 (en) 2011-10-27
EP1663970B1 (en) 2008-11-05
ATE502922T1 (de) 2011-04-15
EP2042488A1 (en) 2009-04-01
KR20120007566A (ko) 2012-01-20
CA2538315A1 (en) 2005-03-24
WO2005026120A1 (en) 2005-03-24
US20090082377A1 (en) 2009-03-26
NO20060540L (no) 2006-04-04
IS8268A (is) 2006-01-26
US7601729B2 (en) 2009-10-13
SI1663970T1 (sl) 2009-04-30
KR20130079628A (ko) 2013-07-10
HRP20080668T3 (en) 2009-02-28
RU2006106850A (ru) 2007-10-20
EP2295408A1 (en) 2011-03-16
DE602004017622D1 (de) 2008-12-18
PL1663970T3 (pl) 2009-04-30
JP2007505081A (ja) 2007-03-08
US20100029699A1 (en) 2010-02-04
US20060293353A1 (en) 2006-12-28
ATE413384T1 (de) 2008-11-15
CY1109400T1 (el) 2014-07-02
SG145685A1 (en) 2008-09-29
MA28039A1 (fr) 2006-07-03
CA2538315C (en) 2014-04-08
EP1663970A1 (en) 2006-06-07
IS2622B (is) 2010-05-15
JP2011231118A (ja) 2011-11-17
CN1849306B (zh) 2014-01-29
PT1663970E (pt) 2009-01-09
DE602004031991D1 (de) 2011-05-05

Similar Documents

Publication Publication Date Title
IS8843A (is) Hálfmálmaprótínasa hindra mót
ATE362910T1 (de) Matrix metalloprotease inhibitoren
BR0201697A (pt) Compostos de alfa-aminoácid0, processo para a sua preparação e composições farmacêuticas contendo os mesmos
NO904569D0 (no) Benzimidazolderivater og fremgangsmaate for deres fremstilling.
SE8008680L (sv) Basiska etrar, sett for deras framstellning och farmaceutiska beredningar innehallande dem
EA200300044A1 (ru) Новые замещенные фталиды, способ их получения и содержащие их фармацевтические композиции
BG106847A (en) Substituted piperazine derivatives as mtp inhibitors
EA199901034A3 (ru) Новые соединения 1,2-дитиолана, способ их получения и содержащие их фармацевтические составы
ATE239021T1 (de) Metalloproteaseinhibitoren, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
GB1398687A (en) Substituted oxazolidinones and pharmaceutical uses thereof
DK1188752T3 (da) Fremgangsmåde til fremstilling af substitueret alkylaminderivat
ES2058182T3 (es) Analogos de mitomicina. un procedimiento para su preparacion y composiciones farmaceuticas.
GB1183442A (is)
PT955310E (pt) Novos derivados do acido (3,4,7,8,9,10)-hexa-hidro-6,10-dioxo-6h-piridazino[1,2-a] [1,2]diazepina-1-carboxilico, seu metodo de preaparacaoe sua aplicacao na preparacao de medicamentos